A Phase 1 First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

PURPOSE: TRC105 is a chimeric IgG1 monoclonal antibody that binds CD105 (endoglin). This first-in-human, phase 1, open label study assessed safety, pharmacokinetics, and antitumor activity of TRC105 in patients with advanced refractory solid tumors. PATIENTS AND METHODS: Patients received escalating...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rosen, Lee S., Hurwitz, Herbert I., Wong, Michael K., Goldman, Jonathan, Mendelson, David S., Figg, William D., Spencer, Shawn, Adams, Bonne J., Alvarez, Delia, Seon, Ben K., Theuer, Charles P., Leigh, Bryan R., Gordon, Michael S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3432706/
https://ncbi.nlm.nih.gov/pubmed/22767667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-0098
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados